Interplay between histone deacetylases and autophagy - From cancer therapy to neurodegeneration

Immunology and Cell Biology

Volumn 90, Issue 1, 2012, Pages 78-84

  Trüe, Oliver ^a   Matthias, Patrick ^a  

^a FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH   (Switzerland)

Author keywords

aggresome; autophagy; HDAC6; histone deacetylase; neurodegeneration; protein degradation

Indexed keywords

HISTONE DEACETYLASE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE 4; HISTONE DEACETYLASE 5; HISTONE DEACETYLASE 6; HISTONE DEACETYLASE 7; HISTONE DEACETYLASE 8; PROTEASOME; ROMIDEPSIN; VORINOSTAT;

ACTIN POLYMERIZATION; AGGRESOME; AUTOPHAGOSOME; AUTOPHAGY; BINDING AFFINITY; BREAST CANCER; CANCER CELL; CELL CYCLE ARREST; CELL SURVIVAL; CUTANEOUS T CELL LYMPHOMA; ENDOPLASMIC RETICULUM; HELA CELL; HISTONE UBIQUITINATION; HUMAN; LIVER CELL CARCINOMA; LYSOSOME; MOLECULARLY TARGETED THERAPY; NERVE DEGENERATION; NERVE SHEATH TUMOR; OVARY CANCER; OXIDATIVE STRESS; PROTEIN DEGRADATION; PROTEIN FOLDING; PROTEIN SYNTHESIS INHIBITION; REVIEW; SIGNAL TRANSDUCTION; UNFOLDED PROTEIN RESPONSE;

AUTOPHAGY; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; NEURODEGENERATIVE DISEASES; SIGNAL TRANSDUCTION;

EID: 84855424390     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/icb.2011.103     Document Type: Review

References (66)

1. Choudhary C, Kumar C, Gnad F, Nielsen ML, Rehman M, Walther TC et al. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 2009; 325: 834-840.
2. Yang XJ, Seto E. The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to miceand men. Nat Rev 2008; 9: 206-218. (Pubitemid 351301825)
3. Haberland M, Montgomery RL, Olson EN. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet 2009; 10: 32-42.
4. Keogh MC, Kurdistani SK, Morris SA, Ahn SH, Podolny V, Collins SR et al. Cotranscrip-tional set2 methylation of histone H3 lysine 36 recruits a repressive Rpd3 complex. Cell 2005; 123: 593-605. (Pubitemid 41608463)
5. Guenther MG, Lane WS, Fischle W, Verdin E, Lazar MA, Shiekhattar R. A core SMRT corepressor complex containing HDAC3 and TBL1, a WD40-repeat protein linked to deafness. Genes Dev 2000; 14: 1048-1057. (Pubitemid 30324419)
6. Jacob C, Christen CN, Pereira JA, Somandin C, Baggiolini A, Lotscher P et al. HDAC1 and HDAC2 control the transcriptional program of myelination and the survival of Schwann cells. Nat Neurosci 2011; 14: 429-436.
7. Dovey OM, Foster CT, Cowley SM. Histone deacetylase 1 (HDAC1), but not HDAC2, controls embryonic stem cell differentiation. Proc Natl Acad Sci USA 2010; 107: 8242-8247.
8. Lagger G, O'Carroll D, Rembold M, Khier H, Tischler J, Weitzer G et al. Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression. EMBOJ 2002; 21: 2672-2681. (Pubitemid 34619383)
9. Montgomery RL, Davis CA, Potthoff MJ, Haberland M, Fielitz J, Qi X et al. Histone deacetylases 1 and 2 redundantly regulate cardiac morphogenesis, growth, and contractility. Genes Dev 2007; 21: 1790-1802. (Pubitemid 47076478)
10. Wu J, Carmen AA, Kobayashi R, Suka N, Grunstein M. HDA2 and HDA3 are related proteins that interact with and are essential for the activity of the yeast histone deacetylase HDA1. Proc Natl Acad Sci USA 2001; 98: 4391-4396. (Pubitemid 32294987)
11. Mihaylova MM, Vasquez DS, Ravnskjaer K, Denechaud PD, Yu RT, Alvarez JG et al. Class IIa histone deacetylases Are hormone-activated regulators of FOXO and mamma-lian glucose homeostasis. Cell 2011; 145: 607-621.
12. Lee JH, Jeong EG, Choi MC, Kim SH, Park JH, Song SH et al. Inhibition of histone deacetylase 10 induces thioredoxin-interacting protein and causes accumulation of reactive oxygen species in SNU-620 human gastric cancer cells. Mol Cells 2010; 30: 107-112.
13. Boyault C, Gilquin B, Zhang Y, Rybin V, Garman E, Meyer-Klaucke Wet al. HDAC6-p97/ VCP controlled polyubiquitin chain turnover. EMBOJ 2006; 25: 3357-3366. (Pubitemid 44141793)
14. Hubbert C, Guardiola A, Shao R, Kawaguchi Y, Ito A, Nixon A et al. HDAC6 is a microtubule-associated deacetylase. Nature 2002; 417: 455-458. (Pubitemid 34563539)
15. Zhang Y, Li N, Caron C, Matthias G, Hess D, Khochbin S et al. HDAC-6 interacts with and deacetylates tubulin and microtubules in vivo. EMBO J 2003; 22: 1168-1179. (Pubitemid 36313600)
16. Zhang X, Yuan Z, Zhang Y, Yong S, Salas-Burgos A, Koomen J et al. HDAC6 modulates cell motility by alteringtheacetylation level ofcortactin. Mol Cell 2007; 27: 197-213. (Pubitemid 47058299)
17. Matthias P, Yoshida M, Khochbin S. HDAC6 a new cellular stress surveillance factor. Cell Cycle 2008; 7: 7-10.
18. Kovacs JJ, Murphy PJ, Gaillard S, Zhao X, Wu JT, Nicchitta CVet al. HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol Cell 2005; 18: 601-607. (Pubitemid 40726236)
19. Kawaguchi Y, Kovacs JJ, Mc Laurin A,Vance JM, Ito A,Yao TP.The deacetylase HDAC6 regulatesaggresomeformation and cellviability in responseto misfolded proteinstress. Cell 2003; 115: 727-738. (Pubitemid 38030301)
20. Kwon S, Zhang Y, Matthias P. The deacetylase HDAC6 is a novel critical component of stress granules involved in the stress response. Genes Dev 2007; 21: 3381-3394.
21. Lee JY, Koga H, Kawaguchi Y, Tang W, Wong E, Gao YS et al. HDAC6 controls autophagosome maturation essential for ubiquitin-selective quality-control autophagy EMBOJ 2010; 29: 969-980.
22. Pandey UB, Nie Z, Batlevi Y, Mc Cray BA, Ritson GP, Nedelsky NB et al. HDAC6rescues neurodegeneration and provides an essential link between autophagy and the UPS. Nature 2007; 447: 859-863. (Pubitemid 46920134)
23. Esteller M. Epigenetics in cancer. N Engl J Med 2008; 358: 1148-1159.
24. Mehnert JM, Kelly WK. Histone deacetylase inhibitors: biology and mechanism of action. Cancer J 2007; 13: 23-29.
25. Glozak MA, Seto E. Histone deacetylases and cancer. Oncogene 2007; 26: 5420-5432. (Pubitemid 47255924)
26. Shao Y, Gao Z, Marks PA, Jiang X. Apoptotic and autophagic cell death induced by histone deacetylase inhibitors. Proc Natl Acad Sci USA 2004; 101: 18030-18035. (Pubitemid 40054069)
27. Klionsky DJ. Autophagy: from phenomenology to molecular understanding in lessthan adecade. Nat Rev 2007; 8: 931-937. (Pubitemid 47622558)
28. Todde V, Veenhuis M, van der Klei IJ. Autophagy: principles and significance in health and disease. Biochimica et Biophysica Acta 2009; 1792: 3-13.
29. Dunn Jr WA. Studies on the mechanisms of autophagy: formation of the autophagic vacuole. JCell Biol 1990; 110: 1923-1933.
30. Geng J, Klionsky DJ. The Atg8 and Atg12 ubiquitin-like conjugation systems in macroautophagy 'Protein modifications: beyond the usual suspects' review series. EMBO Rep 2008; 9: 859-864.
31. Nedelsky NB, Todd PK, Taylor JP. Autophagy and the ubiquitin-proteasome system: collaborators in neuroprotection. Biochimica et Biophysica Acta 2008; 1782: 691-699.
32. Schubert U, Anton LC, Gibbs J, Norbury CC, Yewdell JW, Bennink JR. Rapid degrada-tion of a large fraction of newly synthesized proteins by proteasomes. Nature 2000; 404: 770-774. (Pubitemid 30212405)
33. Plemper RK, Wolf DH. Retrograde protein translocation: ERADication of secretory proteins in health and disease. Trends Biochem Sci 1999; 24: 266-270. (Pubitemid 29301690)
34. Rubinsztein DC The roles of intracellular protein-degradation pathways in neuro-degeneration. Nature 2006; 443: 780-786. (Pubitemid 44622682)
35. Mani A, Gelmann EP. The ubiquitin-proteasome pathway and its role in cancer. J Clin Oncol 2005; 23: 4776-4789. (Pubitemid 46224082)
36. Piazza FA, Gurrieri C, Trentin L, Semenzato G. Towards a new age in the treatment of multiple myeloma. Ann Hematol 2007; 86: 159-172. (Pubitemid 46195988)
37. Ellis RJ. Molecular chaperones: pathways and networks. Curr Biol 1999; 9: R137-R139. (Pubitemid 29120376)
38. Ding WX, Yin XM. Sorting, recognition and activation of the misfolded protein degradation pathways through macroautophagy and the proteasome. Autophagy 2008; 4: 141-150.
39. Bedford L, Lowe J, Dick LR, Mayer RJ, Brownell JE. Ubiquitin-likeprotein conjugation and the ubiquitin-proteasome system as drugtargets. Nat Rev Drug Discov 2011; 10: 29-46.
40. Garcia-Mata R, Gao YS, Sztul E. Hassles with taking out the garbage: aggravating aggresomes. Traffic 2002; 3: 388-396. (Pubitemid 34746406)
41. Fortun J, Dunn Jr WA, Joy S, Li J, Notterpek L. Emerging role for autophagy in the removal of aggresomes in Schwann cells. J Neurosci 2003; 23: 10672-10680. (Pubitemid 37485281)
42. Taylor JP, Tanaka F, Robitschek J, Sandoval CM, Taye A, Markovic-Plese S et al. Aggresomes protect cells by enhancingthe degradation oftoxic polyglutamine-contain-ing protein. Hum Mol Genet 2003; 12: 749-757. (Pubitemid 36416961)
43. Tanaka M, Kim YM, Lee G, Junn E, Iwatsubo T, Mouradian MM. Aggresomes formed by alpha-synuclein and synphilin-1 are cytoprotective. J Biol Chem 2004; 279: 4625-4631. (Pubitemid 38199054)
44. Brodsky JL, Scott CM. Tipping the delicate balance: defining howproteasomematura-tion affects the degradation of a substrate for autophagy and endoplasmic reticulum associated degradation (ERAD). Autophagy 2007; 3: 623-625. (Pubitemid 350060064)
45. Hendershot LM. The ER function Bi P is a master regulator of ER function. Mt Sinai J Med 2004; 71: 289-297.
46. Rikiishi H. Autophagic and apoptotic effects of HDAC inhibitors on cancer cells. JBiomed Biotechnol 2011; 2011: 830260.
47. Yang ZJ, Chee CE, Huang S, Sinicrope F. Autophagy modulation for cancer therapy. Cancer Biol Ther 2011; 11: 169-176.
48. Lopez G, Torres K, Lev D. Autophagy block adeenhances HDAC inhibitors' pro-apoptotic effects: potential implications for the treatment of a therapeutic-resistant malignancy. Autophagy 2011; 7: 440-441.
49. Li J, Liu R, Lei Y, Wang K, Lau QC, Xie N et al. Proteomic analysis revealed association of aberrant ROS signaling with suberoylanilide hydroxamic acid-induced autophagy in Jurkat T-leukemiacells. Autophagy 2010; 6: 711-724.
50. Thomas S, Thurn KT, Bicaku E, Marchion DC, Munster PN. Addition of a histone deacetylase inhibitor redirects tamoxifen-treated breast cancer cells into apoptosis, which is opposed by the induction of autophagy. Breast Cancer Res Treat 2011; 130: 437-447.
51. Liu YL, Yang PM, Shun CT, Wu MS, Weng JR, Chen CC. Autophagy potentiatestheanti-cancer effects of the histone deacetylase inhibitors in hepatocellular carcinoma. Autophagy 2010; 6: 1057-1065.
52. Hrzenjak A, Kremser ML, Strohmeier B, Moinfar F, Zatloukal K, Denk H. SAHA induces caspase-independent, autophagic cell death of endometrial stromal sarcoma cells by influencing the m TOR pathway J Pathol 2008; 216: 495-504.
53. Oh M, Choi IK, Kwon HJ. Inhibition of histone deacetylase1 induces autophagy. Biochem Biophys Res Commun 2008; 369: 1179-1183.
54. Cao DJ, Wang ZV, Battiprolu PK, Jiang N, Morales CR, Kong Yet al. Histonedeacetylase (HDAC) inhibitors attenuate cardiac hypertrophy by suppressing autophagy. Proc Natl Acad Sci USA 2011; 108:4123-4128.
55. Boyault C, Zhang Y, Fritah S, Caron C, Gilquin B, Kwon SH et al. HDAC6 controls major cell response pathways to cytotoxic accumulation of protein aggregates. Genes Dev 2007; 21: 2172-2181. (Pubitemid 47360839)
56. Iwata A, Riley BE, Johnston JA, Kopito RR. HDAC6 and microtubules are required for autophagic degradation of aggregated huntingtin. J Biol Chem 2005; 280: 40282-40292. (Pubitemid 41779165)
57. Ju JS, Miller SE, Hanson PI, Weihl CC. Impaired protein aggregate handling and clearance underlie the pathogenesis of p97/VCP-associated disease. J Biol Chem 2008; 283: 30289-30299.
58. Bobrowska A, Paganetti P, Matthias P, Bates GP. Hdac6 knock-out increases tubulin acetylation but does not modify disease progression in the R6/2 mouse model of Huntington's disease. Plo S One 2011; 6: e20696.
59. Milani M, Rzymski T, Mellor HR, Pike L, Bottini A, Generali D et al. The role of ATF4 stabilization and autophagy in resistance of breast cancer cells treated with Bortezo-mib. Cancer Res 2009; 69: 4415-4423.
60. Perez M, Santa-Maria I, Gomez de Barreda E, Zhu X, Cuadros R, Cabrero JR et al. Tau-an inhibitor of deacetylase HDAC6 function. J Neurochem 2009; 109: 1756-1766.
61. Ding H, Dolan PJ, Johnson GV. Histone deacetylase 6 interacts with the microtubule-associated proteintau. J Neurochem 2008; 106: 2119-2130.
62. Guthrie CR, Kraemer BC. Proteasome inhibition drives HDAC6-dependent recruitment of tau to aggresomes. J Mol Neurosci 2011; 45: 32-41.
63. Jiang Q, Ren Y, Feng J. Direct binding with histone deacetylase 6 mediates the reversible recruitment of parkin to the centrosome. J Neurosci 2008; 28: 12993-13002.
64. Lee JY, Nagano Y, Taylor JP, Lim KL, Yao TP. Disease-causingmutations in parkin impair mitochondrial ubiquitination, aggregation, and HDAC6-dependent mitophagy. J Cell Biol 2010; 189: 671-679.
65. Du G, Liu X, Chen X, Song M, Yan Y, Jiao R et al. Drosophila histone deacetylase 6 protects dopaminergic neurons against {alpha}-synuclein toxicity by promoting inclu-sionformation. Mol Biol Cell 2010; 21: 2128-2137.
66. Rivieccio MA, Brochier C, Willis DE, Walker BA, D'Annibale MA, Mc Laughlin K et al. HDAC6 is a target for protection and regeneration following injury in the nervous system. Proc Natl Acad Sci USA 2009; 106: 19599-19604.